| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V31917 | EC330 | 2016795-77-8 | EC330 is a leukemia inhibitory factor (LIF) inhibitor. |
|
V21579 | GIBH-130 | 1252608-59-5 | GIBH-130 is a neuroinflammation inhibitor. |
|
V12909 | JTE-607 HCl | 188791-09-5 | JTE-607 HCl, the hydrochloride of JTE607, is a potent inhibitor of inflammatory cytokine production with the potential for the treatment of systemic inflammatory response. |
|
V26690 | NSC 247030 | 114727-43-4 | SU5201 inhibits interleukin-2 (IL-2) production. |
|
V13636 | RCGD-423 | 108237-91-8 | RCGD423 is a gp130 modulator that prevents articular cartilage degradation and promotes its repair. |
|
V2974 | YM-90709 | 163769-88-8 | YM-90709 is a novel antagonist of interleukin-5 receptor which inhibits the binding of interleukin-5 to interleukin-5 receptor. |
|
V1966 | Diacerein (Diacerhein) | 13739-02-1 | Diacerein (Diacerhein; Diacetylrhein) isslow-acting medication which acts asa potent inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, it is indicated for osteoarthritis and chronic inflammatory arthritis. |
|
V14140 | Eupafolin | 520-11-6 | Nepetin (6-Methoxyluteolin) is a naturally occurring flavonoid extracted from Eupatorium ballotaefolium HBK and has potent anti~inflammatory activity. |
|
V2089 | Suplatast Tosylate (IPD 1151T) | 94055-76-2 | Suplatast Tosilate (also known as IPD-1151T)is a novel capsular anti-asthmatic and anti-allergic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM. |
|
V4142 | Apilimod | 541550-19-0 | Apilimod is a novel and potent small molecular inhibitor of IL-12/IL-23 and has been evaluated in clinical trials for patients with Crohns disease or rheumatoid arthritis. |
|
V4143 | Apilimod mesylate | 870087-36-8 | Apilimod mesylate, the mesylate salt of Apilimod, is a novel and potent small molecular inhibitor of IL-12/IL-23 and has been evaluated in clinical trials for patients with Crohns disease or rheumatoid arthritis. |